China’s Sinolink Securities Co. described MEDIPOST as the ‘Company that sells the most profitable stem cell drug in the world.’

Sinolink Securities Co. in its recent ‘Stem Cell Drug Industry Report’, analyzed the advanced technologies and products of MEDIPOST and described MEDIPOST as one of the leading bio companies in Korea.

This was the first time a Chinese securities company has released a stem cell drug industry report and MEDIPOST is the only Korean company analyzed in this report. Sinolink Securities Co. is one of the 5 top securities companies in China and its headquarters is located at Shanghai.

In this report, Sinolink Securities Co. also explained, “MEDIPOST currently sells the most profitable stem cell drug (CARTISTEM^®) ever released in the world. CARTISTEM^®’s effectiveness has been proven in the market over the past 5 years.”